NDLI: Prevention of Drug Carryover Effects in Studies Assessing Antimycobacterial Efficacy of TMC207▿

Content Provider	PubMed Central
Author	Nacer, Lounis Gevers, Tom Berg, Joke Van Den Verhaeghe, Tom Heeswijk, Rolf Van Andries, Koen
Abstract	The levels of TMC207 (R207910) that can be reached in mouse organs and the sputa of treated patients easily exceed the MIC of the compound and can therefore interfere with in vitro bacterial titrations. We studied the usefulness of protein-enriched media for the prevention of such drug carryover effects. The average MIC of Mycobacterium tuberculosis was determined on three different media: unsupplemented 7H11 agar (MIC = 0.03 μg/ml), 7H11 agar supplemented with 5% bovine serum albumin (BSA; MIC = 1 μg/ml), and Lowenstein-Jensen medium (MIC = 14.33 μg/ml). In a second stage of the study, the maximal noninhibitory concentrations (MNICs) of TMC207 were determined by adding TMC207 to the bacterial inoculum rather than to the culture medium. These MNICs were 0.97 μg/ml for 7H11 agar, 32.33 μg/ml for 7H11 agar with 5% BSA, and 96.33 μg/ml for Lowenstein-Jensen medium. Both protein-enriched media were able to prevent drug carryover effects, but the use of 7H11 medium supplemented with 5% BSA is preferred for practical reasons.
Related Links	http://dx.doi.org/10.1128/jcm.00177-08
Ending Page	2215
Page Count	4
Starting Page	2212
File Format	PDF
ISSN	00951137
e-ISSN	1098660X
Journal	Journal of Clinical Microbiology
Issue Number	7
Volume Number	46
Language	English
Publisher	American Society for Microbiology (ASM)
Publisher Date	2008-07-01
Access Restriction	Open
Rights Holder	American Society for Microbiology (ASM)
Subject Keyword	Microbiology (medical) Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Microbiology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

Quinoline and quinolones: promising scaffolds for future antimycobacterial agents

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis

In-vitro antimycobacterial drug susceptibility testing of non-tubercular mycobacteria by tetrazolium microplate assay

Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

Optimal Activation of Isopsoralen To Prevent Amplicon Carryover

Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Prevention of Drug Carryover Effects in Studies Assessing Antimycobacterial Efficacy of TMC207▿

Similar Documents

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

Quinoline and quinolones: promising scaffolds for future antimycobacterial agents

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis

In-vitro antimycobacterial drug susceptibility testing of non-tubercular mycobacteria by tetrazolium microplate assay

Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

Optimal Activation of Isopsoralen To Prevent Amplicon Carryover

Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Prevention of Drug Carryover Effects in Studies Assessing Antimycobacterial Efficacy of TMC207▿